Evaluation of Ocular Comfort With ISTA Tears vs Systane
Dry Eye DiseaseTo assess the comfort preference of ISTA Tears vs Systane in patients with dry eye disease (DED)
A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With...
Contact Lens Dry EyeThe primary objective of this study is to compare the duration of subject reported comfortable contact lens daily wear time in subjects with a history and current complaint of CLDE during a 29-day treatment period of azithromycin ophthalmic solution, 1%, compared to rewetting drops
Partial Lacrimal Punctual Occlusion
Dry EyeThe purpose of this study is to describe a case series of patients with chronic dry eye submitted to partial punctual occlusion.
Bromfenac 0.09% vs Ketorolac 0.4% for Cyclosporine Induction Phase
Dry Eye DiseaseOcular ComfortTo compare bromfenac 0.09% and ketorolac 0.4% when used concomitantly with cyclosporine ophthalmic emulsion 0.05% in improving patient comfort during the induction phase of treatment for chronic dry eye disease
Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye
Dry EyeThis was a single-center, randomized, double-masked, placebo-controlled, parallel-group, 4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo (vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose bilaterally either TID or QID according to randomization.
Tear Lipid Layer Thickness Changes With Use of Emollient and Non-Emollient Eye Drops
Dry Eye SyndromesKeratoconjunctivitis Sicca6 moreCross-over comparison of lipid layer thickness and dry eye symptoms with two artificial tear formulations.
Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate...
Dry Eye DiseasePatients with mild to moderate dry eye disease will be randomized to receive either NovaTears® or Hydrabak® eye drops as control.
Effect of Cequa™ in Subjects With Dry Eye Disease
Dry Eye DiseaseThis is a Phase 4, multicenter, single arm, 12 week study in subjects with dry eye disease, which is inadequately controlled by cyclosporine 0.05% ophthalmic emulsion.
Femtosecond Small Incision Lenticular Extraction in Comparison to Femtosecond Laser Insitu Keratomileusis...
Dry Eye DiseaseComparison of femtosecond small incision lenticule extraction (FS-SMILE) versus Femtosecond laser Insitu Keratomileusis (FS-LASIK) regarding dry eye disease (DED) and corneal sensitivity (CS) after those refractive surgeries.
Civamide Nasal Solution for the Treatment of Dry Eye
Dry EyeKeratoconjunctivitis sicca (KCS) or Dry Eye Syndrome is a disease of the surface of the eye, tear film, and related ocular tissues. Millions of people suffer from one form of the disease or another and its prevalence increases with age. Dry Eye Syndrome sufferers experience a broad range of symptoms including discomfort, irritation, burning, itching, redness, pain, gritty feeling, foreign body sensation, blurred vision and ocular fatigue. Civamide is a TRPV-1 receptor modulator that causes the initial stimulation of neuropeptide release and subsequent desensitization to further stimulation of the trigeminovascular system. This provides a pharmacological rational for intranasal route of administration for disorders mediated by the trigeminal nerve or involving the cranial nerve. In nine clinical studies of Civamide Nasal Solution, over 50% of the nearly 300 patients who received Civamide via intranasal administration experienced lacrimation (tearing). This led to the hypothesis that Civamide Nasal Solution might be an appropriate treatment for Dry Eye Syndrome.